AL1
Reinduction and Maintenance of Second or Third Remissions in Children With Acute Lymphoblastic and Acute Undifferentiated Leukemia
CL2A Phase II Study of Oral Fludarabine Phosphate in Patients with Previously Untreated B-cell Chronic Lymphocytic Leukemia
HD11A Randomized Phase II Trial of Pembrolizumab and Brentuximab Vedotin versus GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma
HD12A Randomized Phase III Trial with a PET Response Adapted Design Comparing ABVD +/- ISRT with A2VD +/- ISRT in Patients with Previously Untreated Stage IA/IIA Hodgkin Lymphoma (RADAR)
HD4A Clinical Trial of MOPP/ABV Hybrid versus Alternating MOPP/ABVD for Advanced or Recurrent Hodgkin's Disease
HD5Treatment of Advanced Hodgkin's Disease a Randomized Phase III Trial Comparing ABVD versus MOPP/ABV Hybrid
HD6A Phase III Study of Radiotherapy or ABVD Plus Radiotherapy versus ABVD Alone in the Treatment of Early Stage Hodgkin's Disease
HD7A Randomized Phase III Trial of ABVD Versus Stanford V with or without Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
HD8BEACOPP (4 cycles escalated + 4 cycles baseline) versus ABVD (8 cycles) in stage III & IV Hodgkin's lymphoma
HL1A Randomized Comparison of Deoxycoformycin versus Alpha Interferon in Previously Untreated Patients With Hairy Cell Leukemia
LY11A Randomized Phase III Trial Comparing Early High Dose Chemoradiotherapy and an Autologous Stem Cell Transplant to Conventional Dose CHOP Chemotherapy Plus Rituximab for CD20+B-Cell Lymphomas (With Possible Late Autologous Stem Cell Transplant)for Patients With Diffuse Aggressive Non-Hodgkin's Lymphoma in the High-Intermediate/High Risk International Classification Prognostic Groups
LY12A Phase III Study of Gemcitabine, Dexamethasone, and Cisplatin Compared to Dexamethasone, Cytarabine, and Cisplatin Plus/Minus Rituximab [(R) -GDP VS (R) -DHAP] as Salvage Chemotherapy for Patients with Relapsed or Refractory Aggressive Histology Non-Hodgkin's Lymphoma Prior to Autologous Stem Cell Transplant and Followed by Maintenance Rituximab Versus Observation.
LY13A Multi-centre Phase II Trial Investigating the Efficacy and Tolerability of Bortezomib Added to Cyclophosphamide, Vincristine, Prednisone and Rituximab (BCVP-R) for Patients with Advanced Stage Follicular Non-Hodgkin's Lymphoma Requiring Systemic First-Line Treatment
LY16A Phase III Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma
LY17A Multi-stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
LY18A Phase I Master Protocol of Novel Combination Therapy for Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma
LY3A Comparison of Standard BACOP With Escalated BACOP in Patients With Poor Prognosis Non-Hodgkin's Lymphoma
LY4Phase I/II Study of Chemotherapy Intensification for Patients With Poor Prognosis Advanced Stage Aggressive histology Lymphoma: VACOP-B Plus Etoposide and Cyclophosphamide With RhuGM-CSF (VACOP-B/EC/CSF)
MDC1A Randomized Phase II/III Study of Azacitidine in Combination with Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
MY10A Randomized Phase III Study Of Thalidomide And Prednisone As Maintenance Therapy Following Autologous Stem Cell Transplant In Patients With Multiple Myeloma
Inventory
Show Tissue Samples
Disease Site | Trial Code | Patients Accrued | Patients - Blocks | Patients - Slides | Patients - Blocks and/or Slides |
HEMATOLOGIC | AL1 | 2 | 0 | 1 | 1 |
HEMATOLOGIC | CL2 | 128 | 0 | 0 | 0 |
HEMATOLOGIC | HD11 | Open Trial | 11 | 26 | 36 |
HEMATOLOGIC | HD12 | Open Trial | 0 | 2 | 2 |
HEMATOLOGIC | HD4 | 332 | 0 | 1 | 1 |
HEMATOLOGIC | HD5 | 52 | 0 | 35 | 35 |
HEMATOLOGIC | HD6 | 405 | 0 | 125 | 125 |
HEMATOLOGIC | HD7 | 103 | 1 | 2 | 3 |
HEMATOLOGIC | HD8 | 43 | 12 | 29 | 29 |
HEMATOLOGIC | HL1 | 39 | 0 | 1 | 1 |
HEMATOLOGIC | LY11 | 122 | 4 | 14 | 15 |
HEMATOLOGIC | LY12 | 619 | 306 | 312 | 395 |
HEMATOLOGIC | LY13 | 95 | 45 | 19 | 60 |
HEMATOLOGIC | LY16 | 48 | 24 | 14 | 31 |
HEMATOLOGIC | LY17 | Open Trial | 33 | 65 | 71 |
HEMATOLOGIC | LY18 | Open Trial | 6 | 10 | 12 |
HEMATOLOGIC | LY3 | 298 | 0 | 1 | 1 |
HEMATOLOGIC | LY4 | 28 | 0 | 15 | 15 |
HEMATOLOGIC | MDC1 | 34 | 1 | 8 | 9 |
HEMATOLOGIC | MY10 | 332 | 0 | 0 | 0 |
(Core size is 0.6 mm)
Show
Fluid SamplesDisease Site | Trial Code | Patients Accrued | TMA Blocks | Patients on TMA Blocks |
HEMATOLOGIC | AL1 | 2 | 0 | 0 |
HEMATOLOGIC | CL2 | 128 | 0 | 0 |
HEMATOLOGIC | HD11 | Open Trial | 0 | 0 |
HEMATOLOGIC | HD12 | Open Trial | 0 | 0 |
HEMATOLOGIC | HD4 | 332 | 0 | 0 |
HEMATOLOGIC | HD5 | 52 | 0 | 0 |
HEMATOLOGIC | HD6 | 405 | 0 | 0 |
HEMATOLOGIC | HD7 | 103 | 0 | 0 |
HEMATOLOGIC | HD8 | 43 | 0 | 0 |
HEMATOLOGIC | HL1 | 39 | 0 | 0 |
HEMATOLOGIC | LY11 | 122 | 0 | 0 |
HEMATOLOGIC | LY12 | 619 | 8 | 163 |
HEMATOLOGIC | LY13 | 95 | 1 | 1 |
HEMATOLOGIC | LY16 | 48 | 1 | 4 |
HEMATOLOGIC | LY17 | Open Trial | 1 | 1 |
HEMATOLOGIC | LY18 | Open Trial | 0 | 0 |
HEMATOLOGIC | LY3 | 298 | 0 | 0 |
HEMATOLOGIC | LY4 | 28 | 0 | 0 |
HEMATOLOGIC | MDC1 | 34 | 0 | 0 |
HEMATOLOGIC | MY10 | 332 | 0 | 0 |
Disease Site | Trial Code | Patients Accrued | Patients - Whole Blood | Patients - Cellular Component of Blood | Patients - DNA extracted from Blood | Patients - RNA extracted from Blood | Patients - Plasma | Patients - Serum | Patients - Urine | Patients - Buccal |
HEMATOLOGIC | AL1 | 2 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 |
HEMATOLOGIC | CL2 | 128 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HEMATOLOGIC | HD11 | Open Trial | 2 | 0 | 0 | 0 | 2 | 2 | 0 | 0 |
HEMATOLOGIC | HD12 | Open Trial | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HEMATOLOGIC | HD4 | 332 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HEMATOLOGIC | HD5 | 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HEMATOLOGIC | HD6 | 405 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HEMATOLOGIC | HD7 | 103 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HEMATOLOGIC | HD8 | 43 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HEMATOLOGIC | HL1 | 39 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HEMATOLOGIC | LY11 | 122 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HEMATOLOGIC | LY12 | 619 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
HEMATOLOGIC | LY13 | 95 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HEMATOLOGIC | LY16 | 48 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HEMATOLOGIC | LY17 | Open Trial | 88 | 0 | 0 | 0 | 91 | 87 | 0 | 0 |
HEMATOLOGIC | LY18 | Open Trial | 12 | 0 | 0 | 0 | 13 | 13 | 0 | 0 |
HEMATOLOGIC | LY3 | 298 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HEMATOLOGIC | LY4 | 28 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HEMATOLOGIC | MDC1 | 34 | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HEMATOLOGIC | MY10 | 332 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |